retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial just delivered the most powerful weight loss data ever recorded in a 3 trial. At 104 weeks, participants on the 12 mg dose lost an average of 85 pounds Headline results published this week

Research Applications BPC-157 is widely studied for its potential regenerative and protective properties

Overall, while BPC 157 has shown a favorable safety profile in initial studies, it is crucial to conduct more extensive research to fully understand its potential side effects and risks

Ive heard of racing heart, high blood pressure, flushing, headaches, Kahn said, adding that she refuses to prescribe tanning peptides

Hormone shifts during perimenopause and menopause, along with factors like stress, sleep, and relationship dynamics, can all influence sexual desire

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond